Content area
Abstract
Whether or not remyelination can be achieved in chronically demyelinated lesions in multiple sclerosis remains an unanswered question. A binary, cell-specific, functional screening method identified clemastine fumarate-a first generation antihistamine-as capable of inducing oligodendrocyte differentiation and myelination due to off-target antimuscarinic effects17 and was confirmed in a second independent screen.18
Details
Title
Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial
Author
Green, Ari J; Gelfand, Jeffrey M; Cree, Bruce A; Bevan, Carolyn; Boscardin, W John; Feng, Mei; Inman, Justin; Arnow, Sam; Devereux, Michael; Abounasr, Aya; Nobuta, Hiroko; Zhu, Alyssa; Friessen, Matt; Gerona, Roy; von Büdingen, Hans Christian; Henry, Roland G; Hauser, Stephen L; Chan, Jonah R
Pages
2481-2489
Section
Articles
Publication year
2017
Publication date
Dec 2, 2017
ISSN
01406736
e-ISSN
1474547X
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
1973127304
Copyright
Copyright Elsevier Limited Dec 2, 2017